TELA Bio, Inc. (TELA)
| Market Cap | 45.59M -23.3% |
| Revenue (ttm) | 79.91M +6.1% |
| Net Income | -41.18M |
| EPS | -0.78 |
| Shares Out | 45.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 267,738 |
| Open | 1.070 |
| Previous Close | 1.095 |
| Day's Range | 0.980 - 1.120 |
| 52-Week Range | 0.501 - 1.560 |
| Beta | 1.36 |
| Analysts | Buy |
| Price Target | 2.08 (+105.94%) |
| Est. Earnings | Nov 12, 2026 |
About TELA
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile... [Read more]
Financial Performance
In 2025, TELA Bio's revenue was $80.28 million, an increase of 15.84% compared to the previous year's $69.30 million. Losses were -$38.83 million, 2.62% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for TELA stock is "Buy." The 12-month stock price target is $2.08, which is an increase of 105.94% from the latest price.
News
Tela Bio gets FDA clearance for Liora Monofilament Scaffold
Tela Bio (TELA) announced that the FDA has granted 510(k) clearance for the company’s Liora Monofilament Scaffold product. Liora is a fully resorbable surgical mesh device for soft tissue reinforcemen...
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement
MALVERN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction s...
Craig-Hallum bullish on Tela Bio, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of Tela Bio (TELA) with a Buy rating and $2 price target The firm now sees Tela Bio at a potential turning point. In…
Tela Bio initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of Tela Bio (TELA) with a Buy rating and $2 price target
TELA Bio Proxy statement: Proxy filing
TELA Bio filed a proxy statement on September 14, 2026, providing details for shareholder voting and corporate governance matters.
TELA Bio Proxy statement: Proxy filing
TELA Bio filed a proxy statement on September 4, 2026, providing details for shareholder voting and corporate governance matters.
Tela Bio COO, CFO Roberto Cuca steps down
Tela Bio (TELA) announced that Roberto Cuca, COO and CFO, will step down from the role effective immediately. CEO Heather Getz commented, “At the same time, we are implementing a…
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficie...
Tela Bio reports Q2 EPS (20c), consensus (18c)
Reports Q2 revenue $19.29M, consensus $20.01M. “Unfortunately, the financial performance of the business does not reflect the superiority of the portfolio. Our second quarter revenue was negatively im...
Tela Bio withdraws FY26 guidance
The company said, “The Company has withdrawn full-year guidance and will provide an update in the future.”
TELA Bio Earnings Call Transcript: Q2 2026
Q2 2026 revenue declined 4% year-over-year, mainly due to lower PRS sales and competitive pressures, while international and hernia segments showed growth. Leadership transition and cost reduction initiatives are underway, with guidance withdrawn pending a new plan.
TELA Bio Earnings release: Q2 2026
TELA Bio released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
TELA Bio Quarterly report: Q2 2026
TELA Bio has published its Q2 2026 quarterly earnings report on August 10, 2026.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...
Tela Bio appoints Heather Getz as CEO
Tela Bio (TELA) announced that the board of directors has appointed Heather Getz as CEO and director, effective immediately. Getz joins Tela Bio having most recently served as executive VP…
TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director
MALVERN, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction s...
TELA Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
MALVERN, Pa., July 29, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...
TELA Bio to Announce Second Quarter 2026 Financial Results
MALVERN, Pa., July 20, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction sol...
TELA Bio Earnings Call Transcript: Q1 2026
Q1 2026 saw 3% revenue growth to $19.1M, driven by a 41% surge in international sales and 16% OviTex unit growth. The company launched OviTex LTR, expanded its field team, and reaffirmed 8%+ full-year revenue growth guidance, with strong momentum expected in the second half.
TELA Bio Earnings release: Q1 2026
TELA Bio released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
TELA Bio Quarterly report: Q1 2026
TELA Bio has published its Q1 2026 quarterly earnings report on May 12, 2026.
TELA Bio Reports First Quarter 2026 Financial Results
MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today re...
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
MALVERN, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today ...
TELA Bio Proxy statement: Proxy filing
TELA Bio filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
TELA Bio Proxy statement: Proxy filing
TELA Bio filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.